Pancreatic Cancer Research

ResearcherUniversity of AlabamaActive in the last 2 years

Ravi Kumar Paluri

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2317-7082; OpenAlex author ID A5042094731. Sources: ClinicalTrials.gov.

Their work

Papers
15 (first author 0, last author 6)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
37
Papers, trials and grants by year

2017: 1 trial · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers, 2 trials · 2024: 2 papers · 2025: 2 papers · 2026: 2 papers

Papers 15

  1. Metastatic Pancreatic Adenocarcinoma with Germline BLM and Somatic ATM Mutations: A Case Report and Review of DNA Damage Response. Co-author DOI 10.29011/2574-7754.102521↗
  2. Molecular Characterization of Small Extracellular Vesicles in Pancreatic Cancer Patients Treated with Neoadjuvant Chemotherapy Followed by Stereotactic Body Ra… Co-author DOI 10.3390/cancers18111704↗
  3. Real-world clinical outcomes and economic burden of metastatic pancreatic ductal adenocarcinoma: a systematic review. Last author DOI 10.1080/14796694.2024.2435253↗
  4. Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. Co-author DOI 10.3389/fonc.2025.1544928↗
  5. Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy Co-author DOI 10.20944/preprints202409.0945.v1↗
  6. Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. Co-author DOI 10.3390/ijms25169041↗
  7. Time to treatment initiation and its impact on real-world survival in metastatic colorectal cancer and pancreatic cancer. Co-author DOI 10.1002/cam4.5133↗
  8. Predictive Value of MUC5AC Signature in Pancreatic Ductal Adenocarcinoma: A Hypothesis Based on Preclinical Evidence. Last author DOI 10.3390/ijms24098087↗
  9. Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States. Co-author DOI 10.1093/oncolo/oyac029↗
  10. Efficacy and tolerability of the combination of nano-liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma: post-approval cl… Last author DOI 10.21037/jgo-20-338↗
  11. Predictors of Survival among Early Onset Pancreatic Adenocarcinoma Patients A Tertiary Care Center Experience. Last author DOI 10.21614/chirurgia.116.1.24↗
  12. Survival Outcomes of Pancreatic Intraepithelial Neoplasm (PanIN) versus Intraductal Papillary Mucinous Neoplasm (IPMN) Associated Pancreatic Adenocarcinoma. Co-author DOI 10.3390/jcm9103102↗
  13. Second-line treatment for metastatic pancreatic cancer. Co-author PMID 32558804↗
  14. Accurate Therapeutic Response Assessment of Pancreatic Ductal Adenocarcinoma Using Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging With a Poi… Last author DOI 10.1097/rli.0000000000000505↗
  15. Advances in pancreatic cancer biomarkers. Last author DOI 10.4081/oncol.2019.410↗

Trials 3

  1. Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer Principal investigator NCT05776524↗
  2. Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Principal investigator NCT05825066↗
  3. Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Principal investigator NCT03600623↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anup Kasi · 8 shared papers, 2020–2026 · strength 1.53
  2. Ashish Manne · 6 shared papers, 2023–2026 · strength 1.41
  3. Upender Manne · 5 shared papers, 2019–2026 · strength 0.97
  4. Ashwini Kumar Esnakula · 4 shared papers, 2023–2025 · strength 0.78
  5. Paul C. Cockrum · 2 shared papers, 2022–2025 · strength 0.51
  6. Kannan Thanikachalam · 3 shared papers, 2024–2025 · strength 0.51
  7. Wancai Yang · 3 shared papers, 2024–2025 · strength 0.51
  8. Lianbo Yu · 3 shared papers, 2024–2025 · strength 0.51
  9. Ankur Sheel · 3 shared papers, 2024–2025 · strength 0.51
  10. Jordan M. Cloyd · 3 shared papers, 2024–2025 · strength 0.51
  11. Olumide B. Gbolahan · 2 shared papers, 2023–2026 · strength 0.49
  12. Prasad R. Dandawate · 2 shared papers, 2020–2026 · strength 0.43
  13. Deepak Sherpally · 2 shared papers, 2024–2025 · strength 0.36
  14. Syvart Dennen · 1 shared paper, 2025 · strength 0.33
  15. Bhargavram Channagiri Srinivas · 1 shared paper, 2026 · strength 0.32
  16. Gagan Deep · 1 shared paper, 2026 · strength 0.32
  17. Sameek Roychowdhury · 2 shared papers, 2024 · strength 0.31
  18. Mary E. Dillhoff · 2 shared papers, 2024 · strength 0.31
  19. Anne M. Noonan · 2 shared papers, 2024 · strength 0.31
  20. Aslam M. Ejaz · 2 shared papers, 2024 · strength 0.31
  21. Shafia Rahman · 2 shared papers, 2024 · strength 0.31
  22. Timothy McGinnis · 2 shared papers, 2020–2021 · strength 0.28
  23. Timothy Michael Pawlik · 1 shared paper, 2025 · strength 0.21
  24. Lisle Nabell · 1 shared paper, 2023 · strength 0.18
  25. Neda Hashemi‐Sadraei · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.